The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice

European Journal of Haematology

Volumn 93, Issue 2, 2014, Pages 118-128

  Okabe, Hiroshi ^a   Suzuki, Takahiro ^a   Uehara, Eisuke ^a   Ueda, Masuzu ^a   Nagai, Tadashi ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone marrow microenvironment; Erythropoietin; Hematopoiesis; Hematopoietic stem cell; Iron overload; Reactive oxygen species; Thrombopoietin

Indexed keywords

CD16 ANTIGEN; CD32 ANTIGEN; CD34 ANTIGEN; ERYTHROPOIETIN; MESSENGER RNA; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; VASCULAR CELL ADHESION MOLECULE 1; CXCL12 PROTEIN, MOUSE; IRON DEXTRAN; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL FUNCTION; COLONY FORMING CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROID PRECURSOR CELL; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; IN VIVO STUDY; IRON OVERLOAD; MEGAKARYOCYTE ERYTHROID PROGENITOR; MICROENVIRONMENT; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BONE MARROW; C57BL MOUSE; CHEMICALLY INDUCED; GENE EXPRESSION; GENETICS; LIVER; MESENCHYMAL STROMA CELL; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MARROW; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELLULAR MICROENVIRONMENT; CHEMOKINE CXCL12; ERYTHROPOIETIN; GENE EXPRESSION; INSULIN-LIKE GROWTH FACTOR I; IRON OVERLOAD; IRON-DEXTRAN COMPLEX; LIVER; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICROARRAY ANALYSIS; OXIDATIVE STRESS; STEM CELL FACTOR; THROMBOPOIETIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84904264021     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12309     Document Type: Article

References (28)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-95.
2. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001;33:940-59.
3. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005;106:3710-7.
4. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603.
5. Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010;34:864-70.
6. Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 2012;36:1067-70.
7. Okabe H, Suzuki T, Omori T, et al. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. Rinsho Ketsueki 2009;50:1626-9.
8. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007;78:540-2.
9. List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 2012;30:2134-9.
10. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008;120:70-4.
11. Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010;50:1568-70.
12. Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 2012; 97: 1364-71.
13. Reardon TF, Allen DG. Iron injections in mice increase skeletal muscle iron content, induce oxidative stress and reduce exercise performance. Exp Physiol 2009;94:720-30.
14. Sohda T, Okubo R, Kamimura S, Ohkawara T. Hemochromatosis with HFE gene mutation in a Japanese patient. Am J Gastroenterol 2001;96:2487-8.
15. Westwood MA, Sheppard MN, Awogbade M, Ellis G, Stephens AD, Pennell DJ. Myocardial biopsy and T2* magnetic resonance in heart failure due to thalassaemia. Br J Haematol 2005;128:2.
16. Hartmann J, Braulke F, Sinzig U, Wulf G, Maas JH, Konietschke F, Haase D. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk Res 2013;37:327-32.
17. Kling PJ, Dragsten PR, Roberts RA, Dos Santos B, Brooks DJ, Hedlund BE, Taetle R. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br J Haematol 1996;95:241-8.
18. Amer J, Goldfarb A, Fibach E. Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry A 2004;60:73-80.
19. Haq RU, Wereley JP, Chitambar CR. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol 1995;23:428-32.
20. Messa E, Carturan S, Maffe C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010;95:1308-16.
21. Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009;100:970-7.
22. Tehranchi R, Invernizzi R, Grandien A, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005;106:247-53.
23. Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006;12:446-51.
24. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994;265:1445-7.
25. Murone M, Carpenter DA, de Sauvage FJ. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells 1998;16:1-6.
26. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Mansson R, Thoren LA, Ekblom M, Alexander WS, Jacobsen SE. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007;1:671-84.
27. Lu W, Zhao M, Rajbhandary S, et al. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients. Eur J Haematol 2013;91:249-61.
28. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006;25:977-88.